enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

4. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab

5. Merck Reveals Mixed Data From Keytruda/Lynparza Regime In ...

   www.aol.com/finance/merck-reveals-mixed-data...

   On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

8. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   Lifastuzumab vedotin: mab: humanized: phosphate-sodium co-transporter: cancer Ligelizumab [15] mab: humanized: IGHE: severe asthma, chronic spontaneous urticaria: Loncastuximab tesirine [87] [74] Zynlonta: mab: chimeric: CD19: Y: relapsed or refractory large B-cell lymphoma Losatuxizumab vedotin [28] mab: chimeric/ humanized: epidermal growth ...

9. Some Early Forms of Breast Cancer May Not Need Treatment ...

   www.aol.com/early-forms-breast-cancer-may...

   While Colletti was ineligible to join the trial, she essentially received the same protocol as those who were assigned to active monitoring—getting mammograms every six months in the breast with ...